Bayman Neil A, Blackhall Fiona, Jain Pooja, Lee Lip, Thatcher Nick, Faivre-Finn Corinne
Department of Clinical Oncology, Christie Hospital, Manchester, UK.
Clin Lung Cancer. 2008 Mar;9(2):92-101. doi: 10.3816/CLC.2008.n.014.
Lung cancer remains the most common cause of cancer deaths in the United Kingdom, and long-term survival from lung cancer has hardly improved over the past 30 years. The benefit of combined-modality therapy with chemotherapy and radiation therapy in improving survival for patients with inoperable non-small-cell lung cancer (NSCLC) was discovered over 10 years ago. In this comprehensive literature review, we discuss the current status of combined-modality therapy for unresectable stage III NSCLC. The efficacy and toxicity of different chemoradiation therapy regimens are presented. The potential role of novel and targeted therapies and radiation dose escalation is also considered. Finally, recommendations are made for the treatment of unresectable stage III NSCLC.
肺癌仍然是英国癌症死亡的最常见原因，在过去30年里，肺癌患者的长期生存率几乎没有提高。10多年前就发现了化疗和放疗联合治疗对无法手术的非小细胞肺癌（NSCLC）患者生存率的改善作用。在这篇全面的文献综述中，我们讨论了不可切除的III期NSCLC联合治疗的现状。介绍了不同放化疗方案的疗效和毒性。还考虑了新型靶向治疗和放疗剂量递增的潜在作用。最后，针对不可切除的III期NSCLC的治疗提出了建议。
